Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab plus ibrutinib versus ibrutinib plus placebo in relapsed or refractory mantle cell lymphoma
2022-001547-25Phase 3Terminated
- Sponsor
- Oncternal Therapeutics
- Start
- Jan 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Zilovertamab + ibrutinib with Placebo + ibrutinib (2 arms). Primary endpoint: Progression-free survival. Started Jan 2023; status: terminated.
02
Drugs
cirmtuzumabibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2022-001547-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001547-25.